Case Report on Taurolidine Treatment for Gastric Cancer
Author Information
Author(s): Braumann Chris, Winkler Goetz, Rogalla Patrick, Menenakos Charalambos, Jacobi Christoph A
Primary Institution: Charité, Humboldt University, Berlin, Germany
Hypothesis
Can intravenous taurolidine lead to tumor remission in a patient with gastric cancer re-recurrence?
Conclusion
The intravenous treatment with 2% taurolidine led to a histological remission of the tumor growth without any toxicity for the patient.
Supporting Evidence
- The patient showed no signs of toxicity during taurolidine treatment.
- Postmortem histology revealed complete remission of the known metastasized gastric adenocarcinoma.
- CT scans indicated stable disease without tumor progression during treatment.
Takeaway
A patient with gastric cancer was treated with a new drug called taurolidine, and it helped make his tumor go away without making him sick.
Methodology
The patient received 2% taurolidine intravenously for 39 cycles, with monitoring of tumor markers and quality of life.
Limitations
The study is based on a single case, limiting generalizability.
Participant Demographics
58-year-old male with gastric adenocarcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website